James Schoeneck has become CEO of Activx Biosciences (see story, p. 3), and former CEO and chief scientific officer John Kozarich has become president and chief R&D officer of the company. Schoeneck was previously president and CEO of Prometheus Laboratories. Prior to joining Prometheus, he was vice president and general manager of the immunology business unit of Centocor, a division of Johnson & Johnson.
Robin Stracey has been appointed president and chief operating officer of Applied Imaging. Stracey was previously vice president and gen-eral manager of the chromatography and mass spectrometry division of Thermo Electron. Prior to that he was corporate vice president of Dade Behring and general manager of diagnostic company Syva. Stracey holds a BS in life sciences from the University of Nottingham in the UK and has completed the executive program at Stanford University’s School of Business.
Tom Metcalfe has been appointed the head of the new Roche Biomarker Program. This biomarker program developed out of the company’s joint program in applied genomics. But unlike the program in applied genomics, the company said, it also incorporates proteomics and metabalomics. Metcalfe is currently the head of business development and operational excellence at Roche Molecular Diagnostics.
Charles River Laboratories has appointed six new members to its scientific advisory board. These members include: Geoffrey Duyk, president and CSO of Exelixis Pharmaceuticals; Joseph Catino, senior vice president of research at Bayer; William Hancock, chair of bioanalytical chemistry at the Barnett Institute at Northeastern University; Brian Huber, vice president of biology, drug discovery at GlaxoSmithKline; Colin McKerlie, research scientist in integrative biology at The Hospital for Sick Children in Toronto; and Jill Mesirov, chief informatics officer of the Whitehead Institute.
Peter Loescher has been appointed chief operating officer of Amersham PLC, the parent company of Amersham Biosciences. Loescher was previously president of Amersham Health. Loescher will continue to lead Amersham Health in his new role, the company said. Andrew Carr, president of Amersham Biosciences, and Peter Ehrenheim, president of protein separations, will report to Loescher. Prior to joining Amersham in December 2002, Loescher was CEO of Aventis Pharma in Japan. He holds a degree from the Vienna University of Economics and Business Administration.